Intersect ENT (XENT) Stock Price Up -1.4%
Intersect ENT Inc (NASDAQ:XENT) shares rose 1.4% during mid-day trading on Tuesday . The company traded as high as $35.10 and last traded at $32.40. Approximately 216,400 shares traded hands during mid-day trading, a decline of 25% from the average daily volume of 290,252 shares. The stock had previously closed at $32.85.
XENT has been the subject of a number of recent analyst reports. Bank of America upped their price objective on Intersect ENT from $33.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, September 11th. Canaccord Genuity upped their price objective on Intersect ENT from $32.00 to $37.00 and gave the company a “buy” rating in a research note on Wednesday, September 13th. Zacks Investment Research upgraded Intersect ENT from a “hold” rating to a “buy” rating and set a $33.00 price objective for the company in a research note on Thursday, October 5th. Northland Securities restated a “hold” rating and issued a $25.00 price objective on shares of Intersect ENT in a research note on Friday, November 3rd. Finally, BTIG Research restated a “hold” rating on shares of Intersect ENT in a research note on Tuesday, November 7th. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $33.38.
The stock has a market cap of $1,030.00, a P/E ratio of -56.13 and a beta of 0.67.
Intersect ENT (NASDAQ:XENT) last posted its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.05. The company had revenue of $22.31 million during the quarter, compared to the consensus estimate of $21.53 million. Intersect ENT had a negative return on equity of 15.96% and a negative net margin of 19.81%. The firm’s quarterly revenue was up 20.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.22) EPS. sell-side analysts forecast that Intersect ENT Inc will post -0.63 EPS for the current year.
In other news, Director Frederic H. Moll sold 6,700 shares of the stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $28.77, for a total transaction of $192,759.00. Following the completion of the transaction, the director now owns 247,124 shares in the company, valued at approximately $7,109,757.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Lisa D. Earnhardt sold 10,685 shares of the stock in a transaction on Friday, December 15th. The stock was sold at an average price of $31.87, for a total value of $340,530.95. Following the transaction, the insider now owns 487,868 shares of the company’s stock, valued at approximately $15,548,353.16. The disclosure for this sale can be found here. Insiders have sold a total of 126,884 shares of company stock valued at $3,838,019 in the last quarter. 13.70% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently modified their holdings of XENT. Great West Life Assurance Co. Can purchased a new stake in Intersect ENT during the 3rd quarter worth about $116,000. Oppenheimer Asset Management Inc. purchased a new stake in Intersect ENT during the 3rd quarter worth about $117,000. Legal & General Group Plc lifted its holdings in Intersect ENT by 3.8% during the 2nd quarter. Legal & General Group Plc now owns 6,939 shares of the medical equipment provider’s stock worth $193,000 after purchasing an additional 255 shares in the last quarter. Moors & Cabot Inc. purchased a new stake in Intersect ENT during the 2nd quarter worth about $205,000. Finally, Campbell & CO Investment Adviser LLC purchased a new stake in Intersect ENT during the 3rd quarter worth about $228,000. 86.31% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Intersect ENT (XENT) Stock Price Up -1.4%” was first published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/intersect-ent-xent-stock-price-up-1-4/1792319.html.
Intersect ENT Company Profile
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.